[go: up one dir, main page]

AR057909A1 - Proceso para preparar montelukast y compuestos relacionados, que utiliza un compuesto intermediario derivado de un ester sulfonico. - Google Patents

Proceso para preparar montelukast y compuestos relacionados, que utiliza un compuesto intermediario derivado de un ester sulfonico.

Info

Publication number
AR057909A1
AR057909A1 ARP060105063A ARP060105063A AR057909A1 AR 057909 A1 AR057909 A1 AR 057909A1 AR P060105063 A ARP060105063 A AR P060105063A AR P060105063 A ARP060105063 A AR P060105063A AR 057909 A1 AR057909 A1 AR 057909A1
Authority
AR
Argentina
Prior art keywords
intermediate compound
related compounds
compound derived
sulfonic ester
formula
Prior art date
Application number
ARP060105063A
Other languages
English (en)
Inventor
Radomir Skoumal
Arjanne Overeem
Lambertus Thijs
Petr Benovsky
Jakub Castulik
Jie Zhu
Petr Bartos
Original Assignee
Synthon Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthon Bv filed Critical Synthon Bv
Publication of AR057909A1 publication Critical patent/AR057909A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/72—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/75—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing singly-bound oxygen atoms bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Reivindicacion 1: Un compuesto de formula (1) en donde R es un grupo alquilo C1-4 recto o ramificado y es preferiblemente un grupo metilo. Reivindicacion 2: El proceso que comprende hacer reaccionar el compuesto de formula (4) o de formula (3) o una sal de adicion de ácido del mismo con un compuesto de formula (1) de la reivindicacion 1, para formar un compuesto de formula (2) o (5) en donde R es un grupo alquilo C1-4.
ARP060105063A 2005-11-18 2006-11-17 Proceso para preparar montelukast y compuestos relacionados, que utiliza un compuesto intermediario derivado de un ester sulfonico. AR057909A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73775205P 2005-11-18 2005-11-18
US79442906P 2006-04-24 2006-04-24
US82438206P 2006-09-01 2006-09-01

Publications (1)

Publication Number Publication Date
AR057909A1 true AR057909A1 (es) 2007-12-26

Family

ID=37685804

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP060105063A AR057909A1 (es) 2005-11-18 2006-11-17 Proceso para preparar montelukast y compuestos relacionados, que utiliza un compuesto intermediario derivado de un ester sulfonico.
ARP060105061A AR056815A1 (es) 2005-11-18 2006-11-17 PROCESO PARA PREPARAR MONTELUKAST, INTERMEDIARIOS DEL MISMO Y SUS SALES DE ADICIoN Y PROCEDIMIENTO DE PURIFICACIoN DE ÉSTOS Y DE MONTELUKAST
ARP060105062A AR057908A1 (es) 2005-11-18 2006-11-17 Proceso para preparar montelukast e intermediarios del mismo

Family Applications After (2)

Application Number Title Priority Date Filing Date
ARP060105061A AR056815A1 (es) 2005-11-18 2006-11-17 PROCESO PARA PREPARAR MONTELUKAST, INTERMEDIARIOS DEL MISMO Y SUS SALES DE ADICIoN Y PROCEDIMIENTO DE PURIFICACIoN DE ÉSTOS Y DE MONTELUKAST
ARP060105062A AR057908A1 (es) 2005-11-18 2006-11-17 Proceso para preparar montelukast e intermediarios del mismo

Country Status (12)

Country Link
US (5) US7786138B2 (es)
EP (3) EP1960362A1 (es)
JP (1) JP2009515922A (es)
AR (3) AR057909A1 (es)
AT (1) ATE497493T1 (es)
AU (3) AU2006314728A1 (es)
CA (3) CA2598093A1 (es)
DE (1) DE602006019979D1 (es)
IL (1) IL185129A0 (es)
NO (1) NO20074188L (es)
PT (1) PT1954679E (es)
WO (3) WO2007057225A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006054317A1 (en) * 2004-11-19 2006-05-26 Matrix Laboratories Ltd Process for the preparation of novel amorphous montelukast sodium
WO2007005965A1 (en) 2005-07-05 2007-01-11 Teva Paharmaceutical Industries Ltd. Purification of montelukast
AR057909A1 (es) * 2005-11-18 2007-12-26 Synthon Bv Proceso para preparar montelukast y compuestos relacionados, que utiliza un compuesto intermediario derivado de un ester sulfonico.
EP2014650A1 (en) * 2007-07-13 2009-01-14 Lonza Ag Process and intermediate for the production of an intermediate in the production of montelukast
ES2320077B1 (es) 2007-07-31 2010-02-26 Moehs Iberica, S.L. Proceso de preparacion de un antagonista de leucotrienos y de un intermedio del mismo.
CN102046602A (zh) * 2008-04-25 2011-05-04 斯索恩有限公司 制备孟鲁司特中间体的方法
EP2552892A1 (en) 2010-03-31 2013-02-06 KRKA, D.D., Novo Mesto Efficient synthesis for the preparation of montelukast and novel crystalline form of intermediates therein
SG10201503234SA (en) 2010-05-03 2015-06-29 Teikoku Pharma Usa Inc Non-Aqueous Taxane Pro-Emulsion Formulations and Methods of Making and Using the Same
TWI450275B (zh) * 2010-05-19 2014-08-21 Wistron Corp 可提升寫入保護之記憶體系統及相關方法
US8471030B2 (en) 2010-12-06 2013-06-25 Orochem Technologies Inc. Purification of montelukast using simulated moving bed
EP2502910A1 (en) 2011-03-15 2012-09-26 Laboratorios Lesvi, S.L. Camphorsulfonic salt of a key Montelukast intermediate
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987000836A1 (en) * 1985-08-06 1987-02-12 Boehringer Biochemia Robin S.P.A. Pharmaceutically active 2-thiomethyl-substituted-1,4-dihydropyridines
CA2038178A1 (en) 1990-04-05 1991-10-06 Carl C. Greco Niobium alkoxyalkoxides and process for formation
DK0480717T3 (da) 1990-10-12 1999-02-08 Merck Frosst Canada Inc Umættede hydroxyalkylquinolinsyrer som leukotrienantagonister
US5565473A (en) 1990-10-12 1996-10-15 Merck Frosst Canada, Inc. Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
EP0480716A1 (en) * 1990-10-12 1992-04-15 Merck Frosst Canada Inc. Saturated hydroxyalkylquinoline acids as leukotriene antagonists
US5856322A (en) 1990-10-12 1999-01-05 Merck Frosst Canada, Inc. Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
US5266568A (en) 1990-10-12 1993-11-30 Merck Frosst Canada, Inc. Hydroxyalkylquinoline ether acids as leukotriene antagonists
IE920499A1 (en) * 1991-02-21 1992-08-26 Merck Frosst Canada Inc Quinoline-containing ketoacids as leukotriene antagonists
US5270324A (en) 1992-04-10 1993-12-14 Merck Frosst Canada, Inc. Fluorinated hydroxyalkylquinoline acids as leukotriene antagonists
TW448160B (en) 1993-12-28 2001-08-01 Merck & Co Inc Novel dicyclohexylamine salt and process for the preparation of leukotriene antagonists
GB9423511D0 (en) 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
US5585115A (en) 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
US5523477A (en) 1995-01-23 1996-06-04 Merck & Co., Inc. Process for the preparation of 1-(thiomethyl)-cyclopropaneacetic acid
US5869673A (en) 1997-02-28 1999-02-09 Merck & Co., Inc. Process for 3-(2-(7-chloro-2-quinolinyl)ethenyl) - benzaldehyde
CN1420113A (zh) 2001-11-16 2003-05-28 北京上地新世纪生物医药研究所 孟鲁司特钠的制备方法及其制备中间体
CN1171873C (zh) * 2001-12-26 2004-10-20 北京上地新世纪生物医药研究所 一种孟鲁司特钠的制备方法及其制备中间体
US20050107612A1 (en) * 2002-12-30 2005-05-19 Dr. Reddy's Laboratories Limited Process for preparation of montelukast and its salts
US20040265375A1 (en) 2003-04-16 2004-12-30 Platteeuw Johannes J. Orally disintegrating tablets
EP1678139B1 (en) 2003-10-10 2011-08-31 Synhton B.V. Solid-state montelukast
EP1708708A1 (en) * 2004-01-30 2006-10-11 Teva Pharmaceutical Industries Ltd. Montelukast free acid polymorphs
US7189853B2 (en) * 2004-04-15 2007-03-13 Dr. Reddy's Laboratories Limited Process for the preparation of [R-(E)-1-[[[1-[3-[2-[7-chloro-2-quinolinyl]ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropaneacetic acid (Montelukast) and its pharmaceutically acceptable salts
US7829716B2 (en) * 2004-04-30 2010-11-09 Synthon Pharmaceuticals, Inc. Process for making montelukast and intermediates therefor
US7501517B2 (en) * 2004-04-30 2009-03-10 Synthon Ip, Inc. Process for making montelukast and intermediates therefor
WO2006008751A2 (en) * 2004-07-19 2006-01-26 Matrix Laboratories Ltd Process for the preparation of montelukast and its salts
ITMI20050247A1 (it) * 2005-02-18 2006-08-19 Chemi Spa Processo per la preparazione di montelukast
AR057909A1 (es) * 2005-11-18 2007-12-26 Synthon Bv Proceso para preparar montelukast y compuestos relacionados, que utiliza un compuesto intermediario derivado de un ester sulfonico.

Also Published As

Publication number Publication date
AU2006314726A1 (en) 2007-05-24
PT1954679E (pt) 2011-05-05
CA2598093A1 (en) 2007-05-24
NO20074188L (no) 2008-08-13
AR057908A1 (es) 2007-12-26
AU2006314728A1 (en) 2007-05-24
EP1954679A1 (en) 2008-08-13
WO2007057228A1 (en) 2007-05-24
US20070135480A1 (en) 2007-06-14
AU2006314729A1 (en) 2007-05-24
CA2629840A1 (en) 2007-05-24
WO2007057227A1 (en) 2007-05-24
AR056815A1 (es) 2007-10-24
US20100099879A1 (en) 2010-04-22
IL185129A0 (en) 2007-12-03
EP1948610A2 (en) 2008-07-30
WO2007057225A2 (en) 2007-05-24
US20090093636A1 (en) 2009-04-09
US20070135643A1 (en) 2007-06-14
DE602006019979D1 (de) 2011-03-17
ATE497493T1 (de) 2011-02-15
EP1954679B1 (en) 2011-02-02
US7476748B2 (en) 2009-01-13
JP2009515922A (ja) 2009-04-16
WO2007057225A3 (en) 2007-07-26
EP1960362A1 (en) 2008-08-27
US7786138B2 (en) 2010-08-31
CA2629834A1 (en) 2007-05-24
US7601741B2 (en) 2009-10-13
US20070135642A1 (en) 2007-06-14

Similar Documents

Publication Publication Date Title
MA31574B1 (fr) Dérivés de pyrazole et leur utilisation comme inhibiteurs de raf
HRP20120323T1 (en) Diarylhydantoin compounds
GB0418900D0 (en) Novel salt forms
ES2570184T3 (es) Compuestos para dirigir la administración de fármacos y potenciar la actividad de ARNip
AR059010A1 (es) 6-( aril polisustituido )-4- aminopicolinatos y su uso como herbicidas
CO6270211A2 (es) Compuestos nuevos 951 un acido bifeniloxipropanoico como modulador de crth2 e intermedios
TW200736221A (en) Novel pharmaceutical salts and polymorphs of a Factor Xa inhibitor
EA201270216A1 (ru) Фармацевтический состав
AR057909A1 (es) Proceso para preparar montelukast y compuestos relacionados, que utiliza un compuesto intermediario derivado de un ester sulfonico.
WO2007083090A3 (en) Process for the preparation of uracil derivatives
EP3388426A3 (en) Compounds for protection of cells
EA201690072A1 (ru) Состав, содержащий гиполипидемическое средство
EA200802142A1 (ru) Цинковая соль розувастатина
AR063747A1 (es) Definilazetidinona sustituida con acido piperazina-1-sulfonico y que tiene propiedades farmacologicas mejoradas
CR11463A (es) Compuestos de piridilmetil-sulfonamida
AR064658A1 (es) Proceso para preparar duloxetina y sus compuestos relacionados, asi como tambien intermediarios utiles en la misma
HRP20080027T3 (hr) 4-hidroksi-4-metil-piperidin-1-karboksilna kiselina (4-metoksi-7-morfolin-4-il-benzotiazol-2-il)-amid
AR048875A1 (es) Un proceso para preparar montelukast y compuestos intermedios para el mismo
EA200800777A1 (ru) Применение сложных эфиров молочной кислоты для улучшения действия пестицидов
EA201071424A1 (ru) Сульфонатные соли 2-амино-3-карбэтоксиамино-6-(4-фторбензиламино)пиридина
BRPI0808570B8 (pt) processo para a preparação de inibidores de glyt-1
EA200970779A1 (ru) Новое сульфированное соединение сахара и его применение в качестве лекарственного средства
ATE486852T1 (de) Salze von 9-oxoacridin-10-essigsäure mit 1- alkylamino-1-desoxypolyolen
AR082593A1 (es) Proceso para la preparacion de pirazoles
EA200600760A1 (ru) Новые соединения фенилпиридилпиперазина, способ их получения и фармацевтические композиции, содержащие их

Legal Events

Date Code Title Description
FA Abandonment or withdrawal